How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators - EDM Research Series No. 007
(1993; 92 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaIntroduction
Ver el documentoPurpose of drug use indicators
Ver el documentoObjectives of a drug use study
Ver el documentoBackground on the development of drug use indicators
Ver el documentoContents of the manual
Ver el documentoComments on the manual
Abrir esta carpeta y ver su contenidoChapter 1: Overview
Abrir esta carpeta y ver su contenidoChapter 2: Core drug use indicators
Abrir esta carpeta y ver su contenidoChapter 3: Study design and sample size
Abrir esta carpeta y ver su contenidoChapter 4: Planning and field methods
Abrir esta carpeta y ver su contenidoChapter 5: Analysis and reporting
Abrir esta carpeta y ver su contenidoChapter 6: Follow up questions
Abrir esta carpeta y ver su contenidoAnnexes
 

Comments on the manual

The indicators and methods presented in this manual have been extensively reviewed and field tested in many developing countries. However, some unanswered questions remain regarding the implementation of the methodologies in different health environments, and the long-term usefulness of some of the indicators and recommended approaches. It is planned that the indicators in this manual will be developed further as additional field experience with their use is accumulated. It is only when the indicators are actually used by different people in different countries that they can be refined and fully validated.

The WHO Action Programme on Essential Drugs invites any reports on experiences in using these indicators, and comments on practical problems in implementation and analysis. In addition, it would be most valuable to have descriptions of second-level questions addressed after an initial drug use study has been completed, and of actions implemented to improve observed drug use problems. These experiences will be collected by the Action Programme and included in any future revision of this manual. Please send comments and reports to the Action Programme on Essential Drugs, World Health Organization, 1211 Geneva 27, Switzerland.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013